



Vaxart, Inc.  
Investor Relations Department  
2500 Northwinds Parkway  
Suite 100  
Alpharetta, GA 30009  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### NASDAQ: VXRT

Last Trade:	5.94
Trade Time:	1:58 PM ET Mar 19, 2018
Change:	-0.36  (-5.714%)
Day Range	5.78 - 6.25
52-Week Range	4.74 - 11.88
Volume	31,181

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Vaxart is focused on developing oral recombinant protein vaccines administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart's oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. The Company is developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus, a widespread cause of acute gastrointestinal distress for which two Phase 1 human studies hav... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- Mar 7, 2018*  
[Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance](#)
- Mar 2, 2018*  
[Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases](#)
- Feb 14, 2018*  
[Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.](#)
- Feb 9, 2018*  
[Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms](#)
- Feb 9, 2018*  
[Vaxart Provides Merger Update](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 26, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- Feb 6, 2018*  
[Quarterly Report \(10-Q\)](#)